( OTC-BB:SNGX )

News from soligenix, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 20, 2016, 07:00 ET Soligenix Appoints Karen Krumeich, as Chief Financial Officer

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Jun 06, 2016, 07:00 ET Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...


May 31, 2016, 07:00 ET FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


May 26, 2016, 07:00 ET Soligenix to Present at the 2016 Marcum MicroCap Conference

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


May 25, 2016, 07:00 ET Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...


May 12, 2016, 07:00 ET Soligenix Announces Recent Accomplishments and First Quarter 2016 Financial Results

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


May 05, 2016, 07:00 ET Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Apr 14, 2016, 07:00 ET Soligenix Announces Issuance of New Patents for Dusquetide

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...


Mar 29, 2016, 07:00 ET Soligenix Announces Publication of Preclinical Efficacy Results with Dusquetide in Infectious Disease

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Mar 24, 2016, 07:00 ET Soligenix Announces Recent Accomplishments and Year-End 2015 Financial Results

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...


Mar 17, 2016, 07:00 ET Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Feb 02, 2016, 07:00 ET Soligenix to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...


Jan 26, 2016, 07:00 ET Soligenix Provides 2016 Business Outlook

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Dec 16, 2015, 07:00 ET Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Dec 16, 2015, 07:00 ET Soligenix Will Host a Conference Call to Update Shareholders on Recent Positive Clinical Results and Company Development Milestones

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Dec 14, 2015, 07:00 ET Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Dec 09, 2015, 07:00 ET Soligenix Receives $490,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Dec 04, 2015, 07:30 ET Soligenix Provides Clinical Program Updates for December 2015

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...


Nov 12, 2015, 07:00 ET Soligenix Announces Recent Highlights and Third Quarter 2015 Financial Results

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Oct 05, 2015, 07:15 ET Soligenix to Present at the 3rd Annual BioNJ CEO Summit

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...


Aug 31, 2015, 07:00 ET Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...


Aug 27, 2015, 07:15 ET Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...


Aug 19, 2015, 07:00 ET Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...


Aug 12, 2015, 07:00 ET Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...


Aug 04, 2015, 07:30 ET Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...